Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
This study has been completed.
Sponsor:
Boehringer Ingelheim
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00946829
First received: July 24, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in patients with hypertension using home blood pressure measurements.
| Condition | Intervention |
|---|---|
|
Hypertension |
Drug: telmisartan |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Study of Hypertensive Population Under Treatment With Micardis in Real Clinical Conditions With the Goal to Control the Early Morning BP Rise |
Resource links provided by NLM:
Further study details as provided by Boehringer Ingelheim:
Primary Outcome Measures:
- Change from baseline in mean early morning systolic blood pressure, mean early morning diastolic blood pressure, and degree of control. (6:00 to 11:59), BP < 135/85 mmHg. (HBPM: mean of morning measurements). [ Time Frame: 217 Weeks ]
Secondary Outcome Measures:
- Clinical control (office BP), response rates, reduction in office cuff systolic and diastolic BP. Office BP control criteria: BP < 140/90 mmHg. Pulse rate, pulse pressure, discontinuations and tolerability. [ Time Frame: 217 Weeks ]
| Enrollment: | 18299 |
| Study Start Date: | January 2003 |
| Primary Completion Date: | May 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Primary Care Clinic
Criteria
Inclusion Criteria:
- Patients with mild to moderate essential hypertension and whose medical condition make them eligible for treatment with Telmisartan/Telmisartan+HCTZ
Exclusion Criteria:
- Pre-menopausal women who had had no birth control, who are pregnant or nursing
- Patients with advanced hepatic impairment, advanced renal impairment or both
- Patients with functional class III or IV (NYHA) congestive heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months
- Patients with any valvular disease with hemodynamic repercussion
- Patients receiving chronic administration of oral anticoagulants or digoxin
- Patients with known hypersensitivity to any component in the formulation of Micardis / MicardisPlus
- Patients with previous history of angioedema associated with ACE inhibitors
- Patients with severe, uncontrolled hypertension or any form of secondary hypertension
- Patients with any other clinical conditions which, in the opinion of the investigator, would not allow for the safe completion of the protocol
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00946829
Please refer to this study by its ClinicalTrials.gov identifier: NCT00946829
Locations
| Belgium | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Belgium | |
| Canada | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Canada | |
| Colombia | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Colombia | |
| Czech Republic | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Czech Republic | |
| Ecuador | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Ecuador | |
| Indonesia | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Indonesia | |
| Jordan | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Jordan | |
| Lebanon | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Lebanon | |
| Mexico | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Mexico | |
| Turkey | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Turkey | |
| Venezuela | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Venezuela | |
| Yemen | |
| Boehringer Ingelheim Investigational Site | |
| Boehringer Ingelheim Investigational Site, Yemen | |
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
More Information
| Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT00946829 History of Changes |
| Other Study ID Numbers: |
502.425 |
| Study First Received: | July 24, 2009 |
| Last Updated: | July 24, 2009 |
Additional relevant MeSH terms:
|
Telmisartan Antihypertensive Agents Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 25, 2017